Aurobindo Pharma Limited (NSE: AUROPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 733.23B |
| Revenue (ttm) | 302.95B |
| Net Income (ttm) | 35.82B |
| Shares Out | 580.80M |
| EPS (ttm) | 61.31 |
| PE Ratio | 20.59 |
| Forward PE | 17.11 |
| Dividend | 3.00 (0.24%) |
| Ex-Dividend Date | n/a |
| Volume | 564,982 |
| Open | 1,258.80 |
| Previous Close | 1,252.95 |
| Day's Range | 1,246.30 - 1,269.10 |
| 52-Week Range | 958.50 - 1,592.00 |
| Beta | 0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi... [Read more]
Financial Performance
In 2023, Aurobindo Pharma's revenue was 290.02 billion, an increase of 16.68% compared to the previous year's 248.55 billion. Earnings were 31.73 billion, an increase of 64.62%.
Financial StatementsNews
Aurobindo Pharma subsidiary gets approval for oncology biosimilar Bevqolva from UK’s MHRA
Aurobindo Pharma Limited has recently informed exchanges that its subsidiary, CuraTeQ Biologics received approval for its bevacizumab biosimilar, Bevqolva, from the UK’s Medicines and Healthcare produ...
Aurobindo Pharma subsidiary completes US FDA inspection at API Unit V with two minor observations
Aurobindo Pharma Limited has announced the successful completion of a US Food and Drug Administration (US FDA) inspection at Unit V of its wholly-owned subsidiary, Apitoria Pharma Private Limited. The...
Aurobindo Pharma arm CuraTeQ gets positive EMA opinion for biosimilar Zefylti
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefyl...
Aurobindo Pharma shares rise after CuraTeQ’s biosimilar Zefylti gets positive EMA opinion
Shares of Aurobindo Pharma Ltd surged 1.34% on Friday as the company’s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, received a positive opinion for its biosimilar Zefylti from the European ...
Stocks to watch, December 16: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, and Aurobindo Pharma and more in focus today
Here are our stocks to watch today on Dec 16, 2024: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, Aurobindo Pharma, PVR Inox, RITES, Godrej Agrovet, HBL Power, Borosil Renewables, JK Paper ...
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Lookout notice out for Jagan's MP, Aurobindo Pharma official
Andhra Pradesh CID has issued a lookout notice against YSRCP MP Vijayasai Reddy, his son-in-law, and another individual, preventing them from leaving the country. They are accused of extorting shares ...
Aurobindo Pharma arm Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and m...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Aurobindo Pharma shares surge 2% after on strategic collaboration with global pharma major
Aurobindo Pharma shares rose over 2% following its announcement of a collaboration and license agreement with a global pharma major. The partnership focuses on developing and commercializing products ...
Aurobindo Pharma subsidiary signs strategic collaboration for respiratory products with global pharma
Aurobindo Pharma USA Inc., a fully owned subsidiary of Aurobindo Pharma Limited, has entered into a Collaboration and License Agreement with a leading global pharmaceutical company on November 22, 202...
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure
In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...
Aurobindo Pharma Q2 net profit rises 9%
Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance ...
Aurobindo Pharma Q2 FY25 Results: Revenue at ₹7,796.07 crore, up 8.9% YoY; Profit at ₹816.95 crore, up 8.6% YoY
Aurobindo Pharma reported its Q2 FY25 results, showcasing a steady year-on-year (YoY) growth. The company’s total revenue from operations reached ₹7,796.07 crore, marking an 8.9% increase compared to ...
Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally
Lupin Ltd and Aurobindo Pharma Ltd stocks moved upwards in early trade, with Lupin’s shares trading at ₹2,194.50, marking a 0.58% increase, while Aurobindo Pharma stood at ₹1,399.50, up by 0.18% as of...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Quant Active Fund sees 36.74% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma
Quant Active Fund Direct-Growth is Quant Mutual Fund’s equity mutual fund scheme. The fund has an AUM of ₹11,229.42 crores and the current NAV is ₹717.820 as of November 1, 2024. The return performanc...
Quant Mid Cap Fund sees 44.61% returns in last year, top holdings in Reliance Industries & Aurobindo Pharma
Quant Mid Cap Fund Direct-Growth is Quant Mutual Fund’s equity mutual fund scheme. It has an AUM of ₹9,500.70 crores and the latest NAV is ₹253.533 as of November 1, 2024 The return performance of the...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Aurobindo Pharma shares jump 2% after BOCAPS upgrades to ‘Buy’ rating
Aurobindo Pharma shares jumped more than 2% after brokerage firm BOCAPS upgraded the company’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share. Eugia’s sales goal of about US...
BOCAPS upgrades Aurobindo Pharma to ‘Buy’ with a revised target price – check details
BOCAPS has upgraded Aurobindo Pharma’s rating to ‘Buy’, raising the target price from ₹1,200 to ₹1,728 per share. The company is undergoing a transformation, shifting its focus from APIs to biologics ...
Brokerage Updates: Key calls on Zomato, Tata Motors, Nykaa, Zomato, Godrej Properties, Aurobindo Pharma, M&M, Info Edge, and more
Brokerage Reports Highlight Target Prices for Tata Motors, Nykaa, Info Edge, Godrej Properties, Skipper, Trent, Aurobindo Pharma, and more stocks.
UBS maintains sell on Aurobindo Pharma, expects 8% downside from current share price
UBS has maintained a Sell rating on Aurobindo Pharma, with a target price of Rs 1,333, suggesting an 8% downside from the current price of Rs 1,453.00. The rating follows a week-long inspection of Aur...
Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus
Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...